28th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastastasis


Published on

Published in: Health & Medicine, Education
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

28th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastastasis

  1. 1. Harvard Medical School Department of Continuing Education and Massachusetts General Hospital Department of Radiation Oncology Present the Twenty-Eighth Annual Offering of Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: From Bench to Bedside to Biomarkers Monday-Thursday September 30 - October 3, 2013 at the Hotel Marlowe Cambridge, Massachusetts 331063 Tumors 7/23/13 12:41 PM Page 8
  2. 2. Course Description Our 28th Annual Tumor Course will continue to offer the best in critical analysis of what is currently known about the tumor microenvironment, angiogenesis, metastasis and targeted therapies. Our internationally recognized faculty will present their latest findings from their clinics and laboratories. The goal is to highlight key gaps in our present knowledge of can- cer and outline future directions for research at the bench, in the clinic, and in drug development. The course will continue its four-day live lecture format. The faculty will encourage an open discussion and will provide critical comments on the challenges and the future opportuni- ties in research on cancer and in establishment of novel ther- apy approaches and biomarkers to guide treatment. The aim of this course is to analyze and synthesize the most up-to-date findings. Our faculty will present valuable informa- tion in a systematic and comprehensive framework, along with a critical review of various measurement techniques. This course is dedicated to helping improve clinical translation of this knowledge for improved cancer treatment. Learning Objectives Upon completion of this course participants will be able to: • Evaluate molecularly targeted agents approved or currently in clinical development for cancer treatment. • Assess relevant, state-of-the-art or translational pre-clinical models of cancer therapy. • Recognize the steps and determinants of the metastatic process of cancer. • Compare correlative studies of biomarkers and their re- sponse and resistance to targeted therapies in cancer patients. • Analyze state of the art imaging techniques and their applications in pre-clinical and clinical studies will be taught. Target Audience Cancer researchers and clinicians in the pharmaceutical industry, biotechnology industry, federal research laborato- ries, and universities whose research lies in the following areas: • Angiogenesis • Bioengineering • Biomarkers • Biophysics • Biorheology • Chemotherapy • Clinical • Combination Therapies • Diagnostic Radiology • Drug Delivery • Experimental Therapeutics • Gene Therapy • Hematology • Immunotherapy • Inflammation • Lymphatic Vessel Biology • Metabolism • Metastasis • Microcirculation • Molecular Imaging • Monoclonal Antibodies • Nanomedicine • Nanotechnology • Neurology • Nuclear Medicine • Oncology • Pathology • Pathophysiology • Personalized Medicine • PET • Pharmacokinetics • Pharmacology • Photodynamic Therapy • Radiation Biology • Radioimmunodetection • Radioimmunotherapy • Radiotherapy • Surgery • Translational Studies • Tumor Biology • Tumor Microenvironment • Vasculogenesis 331063 Tumors 7/23/13 12:41 PM Page 6
  3. 3. Faculty Lewis C. Cantley, PhD, Professor of Cancer Biology in Medicine, The Margaret and Herman Sokol Professor in Oncology Research, Weill Medical College of Cornell University; Director, The Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY, USA Peter Carmeliet, MD, PhD, Professor of Medicine, Laboratory of Angiogenesis and Neurovascular link; Director, Vesalius Research Center - VRC, Campus Gasthuisberg, KU Leuven, Belgium Lisa M. Coussens, PhD, Hildegard Lamfrom Chair in Basic Science; Professor and Chair, Cell and Developmental Biology; Associate Director for Basic Research, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA Harold F. Dvorak, MD, Mallinckrodt Distinguished Professor of Pathology, Harvard Medical School; Founding Director, Center for Vascular Biology Research - CVBR, Beth Israel Deaconess Medical Center, Boston, MA, USA Napoleone Ferrara, MD, PhD, Distinguished Professor of Pathology, Sr. Deputy Director of Basic Science, Moores Cancer Center, University of California, San Diego, La Jolla, CA Robert S. Kerbel, PhD, Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy; Senior Scientist, Platform Biological Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada Raju Kucherlapati, PhD, Paul C. Cabot Professor of Genetics, Harvard Medical School, Professor of Medicine, Brigham and Women's Hospital, Partners Center for Personalized Medicine, Boston, MA, USA Joan Massagué, PhD, Professor, Weill Graduate School of Medicine, Cornell University; Investigator, Howard Hughes Medical Institute; Chairman, Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Marsha A. Moses, PhD, Julia Dyckman Andrus Professor; Director, Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, MA Jeffrey W. Pollard, PhD, Professor, Department of Developmental and Molecular Biology; Director, Center for the Study of Reproductive Biology and Women’s Health; Louis Goldstein Swan Chair in Women's Cancer Research; Deputy Director, Cancer Center, Albert Einstein College of Medicine, Bronx, NY; also Director MRC University of Edinburgh Centre for Reproductive Health; Professor, College of Medicine and Veterinary Medicine; The Queen’s Medical Research Institute, University of Edinburgh, Scotland George Sledge Jr., MD, Chief, Oncology, Acting Professor, Medicine-Oncology, Department of Medicine, Stanford University, Stanford, CA Daniel D. Von Hoff, MD, FACP, Physician in Chief and Distinguished Professor, TGen-Translational Genomics Research Institute; Professor of Medicine, Mayo Clinic and University of Arizona College of Medicine; Chief Scientific Officer, US Oncology and VGPCC Clinical Trials of Scottsdale Healthcare, Scottsdale, AZ, USA Course Director: Rakesh K. Jain, PhD, Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA Online Information To register or view course information online, visit www.cme.hms.harvard.edu/courses/tumor. To ensure proper registration, please add the first three characters of the source code found at the bottom of the registration form. 331063 Tumors 7/23/13 12:41 PM Page 5
  4. 4. Lecture Schedule Monday, September 30, 2013 7:30 AM Registration 8:00 AM Continental Breakfast 8:30 AM Opening Remarks (Rakesh K. Jain, PhD) 8:45 AM Tumor Microenvironment - I: Angiogenesis and Vascular Transport (Rakesh K. Jain, PhD) 10:00 AM Coffee Break 10:30 AM Tumor Microenvironment - II: Normalization Hypothesis and Biomarkers (Rakesh K. Jain, PhD) Noon Lunch Provided 1:30 PM Tumor Microenvironment III: Interstitium, Lymphatics and Metastasis (Rakesh K. Jain, PhD) 3:00 PM Coffee Break 3:30 PM New Insights in the Role of the Microenvironment in Modulating Tumor Angiogenesis (Napoleone Ferrara, MD, PhD) 5:00 PM Adjourn Tuesday, October 1, 2013 8:00 AM Continental Breakfast 8:30 AM Tumor Stroma Generation: Role of VPF/VEGF (Harold F. Dvorak, MD) 10:00 AM Coffee Break 10:30 AM Developing Translational Models for Adjuvant and Metastatic Therapy using Anti-angiogenic (and other) Drugs with Metronomic Chemotherapy (Robert S. Kerbel, PhD) Noon Lunch (on your own) 1:30 PM Myeloid Cells in Tumor Progression and Metastasis (Jeffrey W. Pollard, PhD) 3:00 PM Coffee Break 3:30 PM Inflammation and Cancer: Targeting Leukocyte Heterogeneity in Solid Tumors as a Therapeutic Tool (Lisa M. Coussens, PhD) 5:00 PM Adjourn Program changes/substitutions may be made without notice. 331063 Tumors 7/23/13 12:41 PM Page 1
  5. 5. Wednesday, October 2, 2013 8:00 AM Continental Breakfast 8:30 AM Mining the Human Proteome: Biomarker Discovery for Human Cancer and Its Metastases (Marsha A. Moses, PhD) 10:00 AM Coffee Break 10:30 AM Metastasis Niches and Pathways (Joan Massagué, PhD) Noon Lunch (on your own) 1:30 PM Lessons from Clinical Trials of Targeted Therapies for Cancer (George W. Sledge, MD) 3:00 PM Coffee Break 3:30 PM Genetics in Cancer Therapy (Raju Kucherlapati, PhD) 5:00 PM Adjourn Thursday, October 3, 2013 8:00 AM Continental Breakfast 8:30 AM Attacking Genomic Hairballs (Daniel D. Von Hoff, MD, FACP) 10:00 AM Coffee Break 10:30 AM PI3 – Kinase and Tumor Metabolism (Lewis C. Cantley, PhD) Noon Lunch Provided 1:30 PM Vessel Branching: Model, Principles and Signals (Peter Carmeliet, MD, PhD) 3:00 PM Coffee Break 3:30 PM Challenges & Opportunities for Anti-Angiogenic Therapy: Metabolism, a Novel Target? (Peter Carmeliet, MD, PhD) 5:00 PM Summary and Closing Remarks (Rakesh K. Jain, PhD) Rave Reviews... "Complicated mechanisms explained in simple and illuminative manner..." "...many thanks for continuing to fuel the intellectual stimulation of so many diverse minds in this vital and important area of research and practice. No course has ever provided comparable revelations to begin to explain what I observe with fascination in daily clinical practice. I greatly look forward to your future courses." from 2011 & 2012 Past Attendees 331063 Tumors 7/23/13 12:41 PM Page 2
  6. 6. Course Details ACCREDITATION: The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Harvard Medical School designates this live activity for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ACGME COMPETENCIES: This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies: • Medical knowledge • Systems-based practice DISCLOSURE POLICY: Harvard Medical School (HMS) ad- adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and oth- ers) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unla- beled or investigational uses of products during their presenta- tions. REGISTRATION INFORMATION Tuition Fee - $995 (USD) Physicians $895 (USD) Residents and Fellows in Training & Allied Health Professionals $700 (USD) for Past Participants of Critical Issues in Tumor Microenvironment Registration by credit card (VISA or MasterCard) can be made at: www.cme.hms.harvard.edu/courses/tumor. Registration by check (draft on a United States bank), please make payable to Harvard Medical School and mail with registration form to Harvard Medical School–Department of Continuing Education, PO Box 417476, Boston, MA 02241-7476. Telephone or fax reg- istration is not accepted. Registration with cash payment is not permitted. Upon receipt of your paid registration an email confir- mation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information including: registration confirmation, evaluation and certificate. INQUIRIES By phone 617-384-8600, Monday-Friday, 10 AM to 4 PM (EST) or by email at: hms-cme@hms.harvard.edu. REFUND POLICY A handling fee of $60 is deducted for cancellation. Refund requests must be received by postal mail, email or fax one week prior to this activity. No refunds will be made thereafter. COURSE LOCATION All sessions will be held at the Hotel Marlowe, 25 Edwin Land Blvd.,Cambridge MA 02141 617-395-2556/Fax: 617-395-2532 www.hotelmarlowe.com ACCOMMODATIONS/TRAVEL A limited number of rooms have been reserved at the Hotel Marlowe (Telephone: 617-395-2525 or 2526) until August 31, 2013. Please specify that you are enrolled in this activity to receive a reduced room rate of $249 per night Single/ Double with 14.45% tax. Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration. For airline reservations contact the HMS Travel Desk toll free 1-877-4-HARVMD (1-877-442- 7863) Monday - Friday 9 AM - 8 PM (EST). From outside the U.S., Canada and Virgin Islands, please call 617-559-3764. ¡ 331063 Tumors 7/23/13 12:41 PM Page 3
  7. 7. Registration Form 28th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: From Bench to Bedside to Biomarkers Class #331063 Sept. 30 - Oct. 3, 2013 Physicians : $995 (USD) Residents and Fellows in Training and Allied Health Professionals: $895 (USD) Past Participants of this activity: $700 (USD) All Fields Required. Please Print Clearly. Full Name __________________________________________ First Middle Initial Last Mailing Address ______________________________________ Street _________________________________________________ City State/Province Zip Code Country Daytime Phone (____)_________________________________ Fax Number (____)___________________________________ Please note: Your email address is used for critical information about the course including: registration confirmation, evaluation and certificate. Please be sure to include an email address you check daily or frequently. Email Address _______________________________________ u Please check if you want to be excluded from receiving email notices of future Harvard Medical School-Department of Continuing Education programs. Profession _________________________________________ Degree ____________________________________________ Primary Specialty (Physicians Only) _________________________ Board Certified: Yes t No t Professional School Attended (Physicians Only) t Harvard Medical School t U.S. Medical School t International Year of Graduation_________________________________________ Online registrants - add the first three characters of the source code found here Source Code: WEB ¡ 331063 Tumors 7/23/13 12:41 PM Page 4